Bookmark and Share
Oxalic Acid (CID 971) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(11)
 
 
Inactive(164)
 
 
Inconclusive(10)
 
 
Unspecified(22)
 
 
Top Targets:
NR LBD PPAR(16)
 
 
 
NR LBD AR(14)
 
 
 
NR LBD ER(14)
 
 
 
NR LBD Fxr(8)
 
 
NR LBD GR(8)
 
 
 
BioAssay Types:
Confirmatory(124)
 
 
 
Summary(48)
 
 
 
Literature(33)
 
 
 
BioActivity Types:
Potency(160)
 
 
 
Ki(6)
 
 
IC50(3)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 113    Data Row: 207   Total Pages: 11   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID46394048]
Ki 17Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB [AID977610, Type: Literature]Chain A, Crystal Structure Of Phosphonopyruvate Hydrolase Complex With Oxalate And Mg++ [gi:116667098]
View
2
[SID46394048]
Ki 17Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB [AID977610, Type: Literature]Chain A, Crystal Structure Of Phosphonopyruvate Hydrolase Complex With Oxalate And Mg++ [gi:116667098]
View
3
[SID46393204]
Ki 24Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB [AID977610, Type: Literature]Chain A, Human Pyruvate Kinase M2 [gi:73535278]
View
4
[SID46393204]
Ki 24Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB [AID977610, Type: Literature]Chain A, Human Pyruvate Kinase M2 [gi:73535278]
View
5
[SID46394255]
Ki 280Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB [AID977610, Type: Literature]Chain A, Structure Of Phosphorylated Enzyme I Of The Phosphoenolpyruvate:sugar Phosphotransferase System [gi:119389970]
View
6
[SID46394255]
Ki 280Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB [AID977610, Type: Literature]Chain A, Structure Of Phosphorylated Enzyme I Of The Phosphoenolpyruvate:sugar Phosphotransferase System [gi:119389970]
View
7
[SID46392737]
IC50 40000Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB [AID977608, Type: Literature]Chain A, Crystal Structure Of Sh2 In Complex With Oxalic Acid. [gi:46015003]
View
8
[SID46392737]
IC50 40000Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB [AID977608, Type: Literature]Chain A, Crystal Structure Of Sh2 In Complex With Oxalic Acid. [gi:46015003]
View
9
[SID46394048]
Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Crystal Structure Of Phosphonopyruvate Hydrolase Complex With Oxalate And Mg++ [gi:116667098]
View
10
[SID46394255]
Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Structure Of Phosphorylated Enzyme I Of The Phosphoenolpyruvate:sugar Phosphotransferase System [gi:119389970]
View
11
[SID46392737]
Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Crystal Structure Of Sh2 In Complex With Oxalic Acid. [gi:46015003]
View
12
[SID103393333]
IC50 40000Inhibitory activity against SH2 domain of human p60 c-Src tyrosine kinase using surface plasmon resonance (SPR) assay. [AID224309, Type: Literature]
View
13
[SID103393333]
Binding energy by using the equation deltaG obsd = -RT ln KD [AID227718, Type: Literature]
View
14
[SID103393333]
Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] [AID1079931, Type: Literature]
View
15
[SID103393333]
Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] [AID1079932, Type: Literature]
View
16
[SID103393333]
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] [AID1079933, Type: Literature]
View
17
[SID103393333]
Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] [AID1079934, Type: Literature]
View
18
[SID103393333]
Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] [AID1079935, Type: Literature]
View
19
[SID103393333]
Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] [AID1079936, Type: Literature]
View
20
[SID103393333]
Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] [AID1079937, Type: Literature]
View